[Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for Japanese patients with advanced non-squamous non-small-cell lung cancer -- a retrospective analysis].

@article{Yamaguchi2015EfficacyAS,
  title={[Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for Japanese patients with advanced non-squamous non-small-cell lung cancer -- a retrospective analysis].},
  author={Teppei Yamaguchi and Toru Nakanishi and Masamichi Hayashi and Sakurako Uozu and Takuya Okamura and Mariko Morishita and Tomoko Takeyama and Tomoyuki Minezawa and Sayako Morikawa and Yoshikazu Niwa and Yuki Mieno and Atsushi Kato and Tami Hoshino and Sumito Isogai and Mitsushi Okazawa and Kazuyoshi Imaizumi},
  journal={Gan to kagaku ryoho. Cancer & chemotherapy},
  year={2015},
  volume={42 2},
  pages={183-7}
}
BACKGROUND Cisplatin plus pemetrexed is considered the standard of care for the first-line treatment of patients with advanced non-squamous non-small-cell lung cancer (NSCLC). However, little is known about the efficacy and safety of this regimen in Japanese patients in a daily clinical setting. METHODS We retrospectively analyzed 40 patients who received cisplatin (75 mg/m/(2)) and pemetrexed (500 mg/m(2)) as a first-line treatment for advanced non-squamous NSCLC. RESULTS Recorded Grade 3… CONTINUE READING